| 1 | CBGI, CD55 |
| Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. | |
| Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. | |
| J Clin Invest 110(9):1269-74. 2002 | |
| 2 | CBGI, CD55 |
| CD55 is over-expressed in the tumour environment. | |
| Li L, Spendlove I, Morgan J, Durrant LG. | |
| Br J Cancer 84(1):80-6. 2001 | |